GlobeNewswire: Tiziana Life Sciences Plc Contains the last 10 of 190 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:33:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/05/2840273/0/en/Tiziana-Life-Sciences-Announces-Podium-Presentation-at-AD-PD-of-Nasal-Anti-CD3-in-Alzheimer-s-Disease.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease2024-03-05T12:00:00Z<![CDATA[NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer’s and Parkinson’s disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.]]>https://www.globenewswire.com/news-release/2024/01/08/2805251/0/en/Tiziana-Life-Sciences-Announces-Updated-Clinical-and-PET-Scan-Findings-for-Intranasal-Foralumab-in-Two-New-Multiple-Sclerosis-Patients.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients2024-01-08T12:00:00Z<![CDATA[NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.]]>https://www.globenewswire.com/news-release/2024/01/05/2804707/0/en/Tiziana-Life-Sciences-to-Present-at-Biotech-Showcase-Conference-in-San-Francisco-January-8-10-2024.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 20242024-01-05T14:30:00Z<![CDATA[NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.]]>https://www.globenewswire.com/news-release/2024/01/05/2804560/0/en/Tiziana-Life-Sciences-Files-New-Patent-Application-for-Combination-Therapy-of-anti-CD3-Foralumab-with-GLP-1-Receptor-Agonist-for-Additional-Reduction-of-Obesity-Associated-Inflamma.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation2024-01-05T12:00:00Z<![CDATA[NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.]]>https://www.globenewswire.com/news-release/2023/12/19/2798422/0/en/Tiziana-Life-Sciences-Doses-First-Patient-in-Phase-2a-Trial-of-Intranasal-Foralumab-in-Multiple-Sclerosis.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis2023-12-19T12:00:00Z<![CDATA[NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status Scale (EDSS), QoL assessments, and the Modified Fatigue Impact Scale (MFIS), which assess parameters that are essential to a patient’s everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images is an integral component of this study.]]>https://www.globenewswire.com/news-release/2023/12/04/2789901/0/en/Tiziana-Life-Sciences-to-Present-at-the-Webull-LIVE-with-Corporate-Connect-Biotech-Investment-Webinar.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar2023-12-04T12:09:38Z<![CDATA[NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana’s recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS) and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s disease.]]>https://www.globenewswire.com/news-release/2023/11/30/2788446/0/en/Tiziana-Life-Sciences-Announces-Foralumab-Dosing-of-Four-New-Patients-in-the-Expanded-Access-Program-for-Multiple-Sclerosis.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis2023-11-30T12:00:00Z<![CDATA[NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access (EA) Program. A total of ten patients are now being followed in the EA Program.]]>https://www.globenewswire.com/news-release/2023/11/01/2770975/0/en/Tiziana-Life-Sciences-to-Present-Recent-Clinical-Updates-at-BIO-Europe-in-Munich-Germany-November-6-8-2023.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 20232023-11-01T11:00:00Z<![CDATA[NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.]]>https://www.globenewswire.com/news-release/2023/10/18/2762186/0/en/Tiziana-Life-Sciences-Announces-Allowance-By-FDA-For-At-Home-Dosing-Of-Intranasal-Foralumab-For-Multiple-Sclerosis-Treatment.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment2023-10-18T11:00:00Z<![CDATA[NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis. The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences. Delivery Device Training materials have been developed and refined in collaboration with the FDA, and patients will be trained in the use of the nasal device in accordance with these materials.]]>https://www.globenewswire.com/news-release/2023/10/16/2760498/0/en/Tiziana-Life-Sciences-Announces-Positive-Six-Month-Clinical-Results-in-Multiple-Sclerosis-Patients-Treated-with-Intranasal-Foralumab.html?f=22&fvtc=4&fvtv=53880Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab2023-10-16T11:00:00Z<![CDATA[NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program. This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023.]]>